Japanese drugmaker Hisamitsu Pharmaceuticals (TYO: 4530), along with US subsidiary Noven Pharmaceuticals, say their transdermal patch for the treatment of schizophrenia (HP-3070, generic name: asenapine maleate) has achieved the primary endpoint of the Phase III clinical trial in the USA.
This study was a Phase III clinical trial to evaluate the efficacy and safety of the investigational product in 617 patients diagnosed with schizophrenia. The primary endpoint of the study was change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score. Efficacy and safety was assessed during the six-week application period.
The study results showed that when compared to placebo the investigational product achieved statistically-significant improvement from baseline in the change of the total PANSS score at six weeks. Secondary endpoints are still under review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze